Brief: Acrux Has Entered Into An Exclusive Commercialisation Agreement With Padagis
20/06/2022 02:24
June 20 (Reuters) - Acrux Ltd ACR.AX :
* HAS ENTERED INTO AN EXCLUSIVE COMMERCIALISATION AGREEMENT
WITH
PADAGIS
* PADAGIS WILL BE RESPONSIBLE FOR COMMERCIALISATION OF CO'S
PRODUCT
Source text for Eikon: urn:newsml:reuters.com:*:nASX9GnZ1F
Further company coverage: ACR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acrux
See all newsBrief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share